CERETEC DIN 02484048
Health Canada record
| Active ingredient(s) | EXAMETAZIME 0.5 MG |
|---|---|
| Dosage form | Powder For Solution; Kit |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V09HA02 TECHNETIUM (99m Tc) EXAMETAZIME LABELLED CELLS |
| Original market date | 15-Apr-2019 |
| Current status date | 15-Apr-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
GE Healthcare Canada Inc. — licence 101469, currently licensed, last inspection rating C (2023-02-06).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing EXAMETAZIME
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02329034 | CERETEC | GE HEALTHCARE CANADA INC | Powder For Solution | EXAMETAZIME 0.5 MG | Marketed |
| 02495848 | DRAX EXAMETAZIME | JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA | Powder For Solution | EXAMETAZIME 0.5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 21643 | 2018-12-21 | Supplement to a New Drug Submission (SNDS) | New stabilizer solution |
International API supply for EXAMETAZIME
1 active FDA Drug Master Files.
Request a quote for CERETEC